Physician profile
Katherine E Smith
NPI 1497998835
$3,381.16
in general payments reported to CMS, 2019-2025
18 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $183 · 2021: $572 · 2022: $957 · 2023: $1,095 · 2024: $271 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $652.06 | 2020-2025 | Austedo, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $503.18 | 2020-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $427.83 | 2019-2022 | |
| Lundbeck LLC | $326.17 | 2020-2024 | Rexulti |
| Alkermes, INC. | $236.67 | 2023-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $231.03 | 2019-2023 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Corium, LLC | $224.86 | 2022-2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $200.08 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $194.69 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $109.64 | 2021-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $82.07 | 2021-2023 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $43.32 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $37.22 | 2023 | Auvelity |
| Indivior INC. | $27.34 | 2023 | Perseris |
| Abbvie INC. | $25.14 | 2023 | Vraylar |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $23.50 | 2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $19.61 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.